Triiodocypropentallylindazole
| File:NVP-420-38-PNG.png | |
| Clinical data | |
|---|---|
| Routes of administration | Inhalational, Intravenous |
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Bioavailability | 99% (Smoked) |
| Metabolism | CYP2D6, DNA Polymerase |
| Elimination half-life | Alpha: 0.891h +/- 0.0008764 h Beta: 9.765h +/- 0.24724 h |
| Duration of action | 4 - 10 hours |
| Identifiers | |
| |
| E number | {{#property:P628}} |
| ECHA InfoCard | {{#property:P2566}} |
Triiodocypropentallylindazole (NVP-420-38) is an orthosteric and allosteric hyperagonist at Cannabinoid Type 1 Receptors and designer drug in the synthetic cannabinoid category and is the most potent synthetic cannabinoid known to man. It is approximately 48.6 octillion times more potent than Delta-9-Tetrahydrocannabinol (Ki = 40.9nM, Emax = 79%). It was developed for Post-Traumatic-Stress-Disorder and Analgesia and displays picogram activity producing a subjective cerebral high comparable to THC
| Target | Binding Affinity (pKi) | Emax | Action |
|---|---|---|---|
| CB1 | 0.00000000000000008417642nM | +3137% | Hyperagonist |
This article "Triiodocypropentallylindazole" is from Wikipedia. The list of its authors can be seen in its historical and/or the page Edithistory:Triiodocypropentallylindazole. Articles copied from Draft Namespace on Wikipedia could be seen on the Draft Namespace of Wikipedia and not main one.
